Learn peptides step by step

What Real-World GLP-1 Data Actually Tells Us About Safety and Results

Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.

Peptide Clinical Evidence in 2026: How to Separate Signal from Hype

Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.

GHK-Cu Topical Gel Trial: What Wound Healing Data Could Show

GHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.

MOTS-c and Mitochondrial Metabolism: What the 2026 Human Trial Is Testing

MOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.

Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means

Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.

BPC-157 Human Hamstring Trial: Why This Study Matters

BPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.

Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch

Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.

Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows

Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.

Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means

31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.

GHK-Cu vs Minoxidil: The Copper Peptide That Outperformed the #1 Hair Loss Treatment

Most people fighting hair loss default to minoxidil. But a 2022 clinical trial showed a 0.5% GHK-Cu serum increased hair count by 22% over 16 weeks — beating 3% minoxidil. And GHK-Cu doesn't just grow hair. It works at the genomic level.

Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss

Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.

Tesamorelin: The Science-Backed Growth Hormone Peptide for Fat Loss and Longevity

Tesamorelin is an FDA-approved GHRH analog with clinical trials proving 15–20% visceral fat reduction. Here's the full science, dosing guide, and what the latest research reveals about its longevity applications.

Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard

Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.

GHK-Cu: The Copper Peptide Accelerating Wound Healing and Skin Regeneration

A 2026 Phase 2 clinical trial confirms GHK-Cu achieves 25% faster wound closure and tissue regeneration versus control. Discover how this naturally occurring copper peptide triggers stem cell activity, collagen synthesis, and anti-inflammatory cascades.

Latest Peptide Research Breakthroughs: What's Coming in 2026

The peptide space is evolving rapidly. Here's what researchers are discovering, which new compounds show promise, and what breakthroughs could hit the market soon.

Retatrutide Phase 3 Results: What the Clinical Data Tells Us

New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.

Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial

Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.

Peptide Research Breakthroughs in 2026: What Clinical Trials Show

2026 marks a pivotal year for peptide research. Here's what the latest clinical data reveals about the most promising peptide candidates and their real-world applications.

Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows

Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.